{"id":707214,"date":"2020-07-31T06:00:00","date_gmt":"2020-07-31T06:00:00","guid":{"rendered":"https:\/\/www.pm360online.com\/?guid=899dd642b224ca729e049fe97023a86d"},"modified":"2020-07-31T06:00:00","modified_gmt":"2020-07-31T06:00:00","slug":"biontech-announces-strategic-collaboration-with-regeneron-to-advance-fixvac-and-libtayo-cemiplimab-combination-in-melanoma-4","status":"publish","type":"post","link":"https:\/\/www.pm360online.com\/biontech-announces-strategic-collaboration-with-regeneron-to-advance-fixvac-and-libtayo-cemiplimab-combination-in-melanoma-4\/","title":{"rendered":"BioNTech Announces Strategic Collaboration with Regeneron to Advance FixVac and Libtayo\u00ae (cemiplimab) Combination in Melanoma"},"content":{"rendered":"<p><![CDATA[MAINZ, Germany, July  31, 2020  (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, \u201cBioNTech\u201d or \u201cthe Company\u201d) today announced a strategic collaboration with Regeneron for a clinical trial combining BioNTech\u2019s BNT111 FixVac product candidate and Libtayo\u00ae (cemiplimab), a fully human anti-PD-1 therapy, for the treatment of melanoma. The companies plan to jointly conduct a randomized Phase 2 study in patients with anti-PD1-refractory\/relapsed, unresectable Stage III or IV cutaneous melanoma. Melanoma is the deadliest skin cancer and estimated to kill more than 63,000 people around the world this year.1]]><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":74553,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[71350,71357],"tags":[],"_links":{"self":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/posts\/707214"}],"collection":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/users\/74553"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/comments?post=707214"}],"version-history":[{"count":0,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/posts\/707214\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/media?parent=707214"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/categories?post=707214"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/tags?post=707214"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}